207 related articles for article (PubMed ID: 22641771)
1. The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity.
Condac E; Strachan H; Gutierrez-Sanchez G; Brainard B; Giese C; Heiss C; Johnson D; Azadi P; Bergmann C; Orlando R; Esmon CT; Harenberg J; Moremen K; Wang L
Glycobiology; 2012 Sep; 22(9):1183-92. PubMed ID: 22641771
[TBL] [Abstract][Full Text] [Related]
2. Novel concatameric heparin-binding peptides reverse heparin and low-molecular-weight heparin anticoagulant activities in patient plasma in vitro and in rats in vivo.
Schick BP; Maslow D; Moshinski A; San Antonio JD
Blood; 2004 Feb; 103(4):1356-63. PubMed ID: 14576044
[TBL] [Abstract][Full Text] [Related]
3. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (II): in vitro evaluation of efficacy and toxicity.
Chang LC; Liang JF; Lee HF; Lee LM; Yang VC
AAPS PharmSci; 2001; 3(3):E18. PubMed ID: 11741269
[TBL] [Abstract][Full Text] [Related]
4. Structural Analysis of Heparin-Derived 3-O-Sulfated Tetrasaccharides: Antithrombin Binding Site Variants.
Chen Y; Lin L; Agyekum I; Zhang X; St Ange K; Yu Y; Zhang F; Liu J; Amster IJ; Linhardt RJ
J Pharm Sci; 2017 Apr; 106(4):973-981. PubMed ID: 28007564
[TBL] [Abstract][Full Text] [Related]
5. A heparin-binding synthetic peptide of heparin/heparan sulfate-interacting protein modulates blood coagulation activities.
Liu S; Zhou F; Höök M; Carson DD
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1739-44. PubMed ID: 9050848
[TBL] [Abstract][Full Text] [Related]
6. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components.
Schroeder M; Hogwood J; Gray E; Mulloy B; Hackett AM; Johansen KB
Anal Bioanal Chem; 2011 Jan; 399(2):763-71. PubMed ID: 20922518
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing the anticoagulant activity of ultra-low-molecular-weight heparins using N-acetylglucosamine 6-sulfatase.
Zhou X; Li L; Linhardt RJ; Liu J
FEBS J; 2013 May; 280(10):2523-32. PubMed ID: 23374371
[TBL] [Abstract][Full Text] [Related]
8. Human antithrombin III-derived heparin-binding peptide, a novel heparin antagonist.
Onoue S; Nemoto Y; Harada S; Yajima T; Kashimoto K
Life Sci; 2003 Oct; 73(22):2793-806. PubMed ID: 14511765
[TBL] [Abstract][Full Text] [Related]
9. Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.
Morla S; Deguchi H; Griffin JH
J Thromb Haemost; 2021 Feb; 19(2):470-477. PubMed ID: 33176060
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin.
Crowther MA; Berry LR; Monagle PT; Chan AK
Br J Haematol; 2002 Jan; 116(1):178-86. PubMed ID: 11841415
[TBL] [Abstract][Full Text] [Related]
11. A non-hemorrhagic hybrid heparin/heparan sulfate with anticoagulant potential.
Brito AS; Cavalcante RS; Palhares LC; Hughes AJ; Andrade GP; Yates EA; Nader HB; Lima MA; Chavante SF
Carbohydr Polym; 2014 Jan; 99():372-8. PubMed ID: 24274520
[TBL] [Abstract][Full Text] [Related]
12. Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (III): preliminary in vivo evaluation of efficacy and toxicity using a canine model.
Lee LM; Chang LC; Wrobleski S; Wakefield TW; Yang VC
AAPS PharmSci; 2001; 3(3):E19. PubMed ID: 11741270
[TBL] [Abstract][Full Text] [Related]
13. Structure-activity relationships of low molecular weight heparins expose to the risk of achieving inappropriate targets in patients with renal failure.
Stratta P; Karvela E; Canavese C; Quaglia M; Lazzarich E; Fenoglio R; Pergolini P; Bellomo G; Cena T; Magnani C
Curr Med Chem; 2009; 16(23):3028-40. PubMed ID: 19689280
[TBL] [Abstract][Full Text] [Related]
14. Platelet factor 4 neutralizes heparan sulfate-enhanced antithrombin inactivation of factor Xa by preventing interaction(s) of enzyme with polysaccharide.
Fiore MM; Kakkar VV
Biochem Biophys Res Commun; 2003 Nov; 311(1):71-6. PubMed ID: 14575696
[TBL] [Abstract][Full Text] [Related]
15. A [+18RGD] protamine variant for nontoxic and effective reversal of conventional heparin and low-molecular-weight heparin anticoagulation.
Wakefield TW; Andrews PC; Wrobleski SK; Kadell AM; Tejwani S; Hulin MS; Stanley JC
J Surg Res; 1996 Jun; 63(1):280-6. PubMed ID: 8661211
[TBL] [Abstract][Full Text] [Related]
16. [Reversal for heparins and new anticoagulant treatments].
Kortchinsky T; Vigué B; Samama CM
Ann Fr Anesth Reanim; 2013 Jan; 32(1):37-49. PubMed ID: 23273505
[TBL] [Abstract][Full Text] [Related]
17. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
[TBL] [Abstract][Full Text] [Related]
18. Chemoenzymatic synthesis of the next generation of ultralow MW heparin therapeutics.
Masuko S; Linhardt RJ
Future Med Chem; 2012 Mar; 4(3):289-96. PubMed ID: 22393937
[TBL] [Abstract][Full Text] [Related]
19. Assays and reference materials for current and future applications of heparins.
Mulloy B; Hogwood J; Gray E
Biologicals; 2010 Jul; 38(4):459-66. PubMed ID: 20338781
[TBL] [Abstract][Full Text] [Related]
20. Combinatorial one-pot chemoenzymatic synthesis of heparin.
Bhaskar U; Li G; Fu L; Onishi A; Suflita M; Dordick JS; Linhardt RJ
Carbohydr Polym; 2015 May; 122():399-407. PubMed ID: 25817684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
